For add-on maintenance treatment of severe asthma in patients with an eosinophilic phenotype aged 12 years or older.
Interleukin (IL)-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa). The IL-5 receptor is expressed on the surface of eosinophils and basophils. It reduces eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity (ADCC).
30 mg SC q4weeks for the first 3 doses, THEN q8weeks thereafter.
Approval was based on three phase 3 studies (ie, CALIMA, SIROCCO, ZONDA), which demonstrated the following:
Up to 51% reduction in the annual asthma exacerbation rate vs placebo.
Significant improvement in lung function as measured by forced expiratory volume in 1 second of up to 159 mL vs placebo, with differences seen as early as 4 weeks after the first dose.
75% median reduction in daily oral corticosteroid use and discontinuation of oral corticosteroid use in 52% of eligible patients.
An overall adverse event profile similar to that of placebo.
FitzGerald JM, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. CALIMA Trial Investigators. Lancet. 2016 Oct29;388(10056):2128-41.
SIROCCO Study Investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115-27.
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.